Imprimis Pharmaceuticals to Host its Fourth Quarter and Fiscal Year 2016 Financial Report Conference Call and Webcast on March 21, 2017 at 4:30 p.m. EDT

SAN DIEGO, March 7, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported it will release fourth quarter and fiscal year 2016 financial results after the close of trading on Tuesday, March 21, 2017.  The company will host a conference call at 4:30 p.m. EDT (1:30 p.m. PDT) on the same day to discuss its financial results and report on recent business developments.

To participate in the call, please dial (877)-407-8035 for domestic callers or (201)-689-8035 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Imprimis website at www.ImprimisRx.com.  A replay of the call will be available until April 21, 2017.  To access the replay, dial (877)-481-4010 domestically or (919)-882-2331 internationally and reference Conference ID: 10212. 

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a pharmaceutical company dedicated to producing and dispensing high quality innovative medications in all 50 states.  The company's unique business model increases patient access and affordability to many critical medicines.  Headquartered in San Diego, California, Imprimis owns and operates three production and dispensing facilities located in California, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisRx.com. 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all; physician interest in prescribing our formulations; risks related to our compounding pharmacy operations; our ability to enter into other strategic alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn, and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at www.sec.gov. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor Contact
Bonnie Ortega
bortega@imprimispharma.com
858-704-4587

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/imprimis-pharmaceuticals-to-host-its-fourth-quarter-and-fiscal-year-2016-financial-report-conference-call-and-webcast-on-march-21-2017-at-430-pm-edt-300419241.html

SOURCE Imprimis Pharmaceuticals, Inc.